StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Wolfe Research on Compass Pathways (CMPS): 'we expect the stock to regain strong momentum after this pullback'
July 7, 2026 3:52 PM
Wolfe Research analyst Rudy Li reiterated an Outperform rating and $18.00 price target on Compass Pathways (NASDAQ: CMPS).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Next Articles
Oppenheimer on Compass Pathways (CMPS): 'Reinforced Durability Strengthens Launch Prospects'
July 7, 2026 12:11 PM
Compass Pathways (CMPS) PT Raised to $25 at BTIG, 'executed nearly flawlessly on everything within its control'
July 7, 2026 12:10 PM
Jefferies on Compass Pathways (CMPS): 'We remain 75-85%+ confident the FDA approves COMP360 (oral psilocybin) around YE:26/early 2027'
July 7, 2026 10:26 AM
Form 8-K COMPASS Pathways plc For: Jul 07
July 7, 2026 6:33 AM
Compass Pathways reports 6-month data from second psilocybin Phase 3 trial
July 7, 2026 6:30 AM
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
July 7, 2026 6:30 AM
Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
July 6, 2026 8:30 AM
